IRIS UniCatt

Orlandi, Armando
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.065
AS - Asia 3.691
EU - Europa 2.911
SA - Sud America 854
Continente sconosciuto - Info sul continente non disponibili 198
AF - Africa 137
OC - Oceania 10
Totale 12.866
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.889
SG - Singapore 1.522
BR - Brasile 699
CN - Cina 662
VN - Vietnam 635
DE - Germania 630
IT - Italia 620
SE - Svezia 456
FR - Francia 272
IN - India 185
GB - Regno Unito 161
BD - Bangladesh 148
PL - Polonia 134
FI - Finlandia 131
IE - Irlanda 131
ID - Indonesia 105
HK - Hong Kong 97
JP - Giappone 85
RU - Federazione Russa 80
CA - Canada 79
AR - Argentina 68
MX - Messico 62
UA - Ucraina 59
NL - Olanda 45
TR - Turchia 42
ES - Italia 41
CI - Costa d'Avorio 38
ZA - Sudafrica 33
IQ - Iraq 32
AT - Austria 30
EC - Ecuador 29
KR - Corea 29
CO - Colombia 21
BE - Belgio 20
IR - Iran 20
SA - Arabia Saudita 20
MA - Marocco 17
LT - Lituania 16
PK - Pakistan 15
PH - Filippine 14
RO - Romania 14
VE - Venezuela 13
CH - Svizzera 11
CZ - Repubblica Ceca 11
MY - Malesia 11
UZ - Uzbekistan 10
CL - Cile 9
NP - Nepal 9
TN - Tunisia 9
AU - Australia 8
EG - Egitto 8
RS - Serbia 8
IL - Israele 7
JM - Giamaica 7
KE - Kenya 7
DZ - Algeria 6
LB - Libano 6
LU - Lussemburgo 6
BG - Bulgaria 5
CR - Costa Rica 5
HN - Honduras 5
HU - Ungheria 5
JO - Giordania 5
KZ - Kazakistan 5
PY - Paraguay 5
SN - Senegal 5
AE - Emirati Arabi Uniti 4
AZ - Azerbaigian 4
BO - Bolivia 4
NO - Norvegia 4
TH - Thailandia 4
AL - Albania 3
ET - Etiopia 3
GE - Georgia 3
LV - Lettonia 3
PE - Perù 3
SK - Slovacchia (Repubblica Slovacca) 3
SV - El Salvador 3
TT - Trinidad e Tobago 3
TW - Taiwan 3
UY - Uruguay 3
BY - Bielorussia 2
CG - Congo 2
EU - Europa 2
GA - Gabon 2
GR - Grecia 2
GT - Guatemala 2
KW - Kuwait 2
LC - Santa Lucia 2
MU - Mauritius 2
NG - Nigeria 2
NI - Nicaragua 2
NZ - Nuova Zelanda 2
OM - Oman 2
PA - Panama 2
PT - Portogallo 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
CD - Congo 1
Totale 12.656
Salva come PNG Salva come JPEG
Città #
Singapore 861
San Jose 536
Ashburn 534
Chandler 487
Ho Chi Minh City 201
Hanoi 168
New York 161
Beijing 145
Los Angeles 134
Chicago 131
Rome 129
Dublin 123
Warsaw 122
Council Bluffs 110
Lauterbourg 101
Munich 95
Hyderabad 89
Hefei 87
Milan 83
The Dalles 80
Hong Kong 79
Fairfield 78
Houston 77
Tokyo 75
Jakarta 74
São Paulo 73
Wilmington 73
Frankfurt am Main 65
San Mateo 64
Boston 55
Helsinki 50
Ann Arbor 48
Princeton 48
Woodbridge 47
Turku 46
Moscow 43
Nanjing 40
Dallas 39
London 39
Abidjan 38
Buffalo 38
Santa Clara 38
Seattle 38
Jacksonville 35
Cattolica 34
Cambridge 33
Orem 33
St Louis 31
Da Nang 30
Dearborn 29
Kent 29
Paris 29
Haiphong 28
Redwood City 28
Toronto 28
Phoenix 27
Marseille 26
Nuremberg 26
Seoul 26
Boardman 25
Chennai 25
Izmir 22
Lappeenranta 22
Montreal 21
Nürnberg 21
Salt Lake City 21
Mexico City 20
Brooklyn 19
Atlanta 18
Bari 18
Brussels 18
Düsseldorf 18
Rio de Janeiro 18
Bremen 16
Denver 16
Dhaka 16
Manchester 16
Poplar 16
San Francisco 16
Stockholm 16
Tampa 16
Johannesburg 15
Tukwila 15
Amsterdam 14
Biên Hòa 14
Elk Grove Village 14
Lancaster 14
Nanchang 14
Porto Alegre 14
Can Tho 13
Guangzhou 13
Hangzhou 13
Genoa 12
Lawrence 12
Madrid 12
Querétaro 12
Salvador 12
Shanghai 12
Vienna 12
Baghdad 11
Totale 6.776
Salva come PNG Salva come JPEG
Nome #
Neoadjuvant chemotherapy in breast cancer: An advanced personalized multidisciplinary prehabilitation model (apmp-m) to optimize outcomes 336
Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? 307
Simultaneous integrated boost intensity-modulated radiotherapy for treatment of bone metastases: analysis of a breast cancer cohort 299
Diagnosis and management of breast lymphoma: A single-institution retrospective analysis 283
KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients 240
Association of IL-8 and eNOS polymorphisms with clinical outcomes in bevacizumab-treated breast cancer patients: an exploratory analysis 229
Diagnosis and treatment of bone metastases in breast cancer: Radiotherapy, local approach and systemic therapy in a guide for clinicians 229
Development of a digital research assistant for the management of patients’ enrollment in oncology clinical trials within a research hospital 204
Mastectomy in precision oncology era: Myth or reality? 193
The likelihood of being helped or harmed as a patient-centred tool to assess cyclin dependent kinase 4/6 inhibitors clinical impact and safety in metastatic breast cancer: a systematic review and sensitivity-analysis 192
Liver metastasectomy for metastatic breast cancer patients: A single institution retrospective analysis 190
Level II Oncoplastic Surgery as an Alternative Option to Mastectomy with Immediate Breast Reconstruction in the Neoadjuvant Setting: A Multidisciplinary Single Center Experience 187
Trastuzumab-induced corneal ulceration: successful no-drug treatment of a "blind" side effect in a case report 185
Liver metastasectomy for metastatic breast cancer patients: A single institution retrospective analysis 170
KRAS Exon 2 Mutations as Prognostic Indicators in Advanced Colorectal Cancer in Clinical Practice: A Mono-Institutional Study 164
Conversion Chemotherapy for Technically Unresectable Colorectal Liver Metastases 164
Development of a digital research assistant for the management of patients’ enrollment in oncology clinical trials within a research hospital 164
Sentinel node biopsy after neoadjuvant chemotherapy for breast cancer: Preliminary experience with clinically node negative patients after systemic treatment 163
Immediate prosthetic breast reconstruction after nipple-sparing mastectomy: Traditional subpectoral technique versus direct-to-implant prepectoral reconstruction without acellular dermal matrix 162
Clinical, pathological and prognostic features of rare braf mutations in metastatic colorectal cancer (Mcrc): A bi-institutional retrospective analysis (rebus study) 161
IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients 158
AMAROS Study: Overall Survival in Breast Cancer Subtypes 156
Neoadjuvant chemotherapy for patients with muscle-invasive urothelial bladder cancer candidates for curative surgery: A prospective clinical trial based on cisplatin feasibility 156
Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapy 153
The impact of multidisciplinary team management on outcome of hepatic resection in liver-limited colorectal metastases 153
191P Radiotherapy (RT) in oligoprogressive metastatic breast cancer (mBC): A retrospective analysis 152
Palbociclib plus fulvestrant or everolimus plus exemestane for pretreated advanced breast cancer with lobular histotype in er+/her2− patients: A propensity score-matched analysis of a multicenter retrospective patient series 151
Dynamics of RAS/BRAF Mutations in cfDNA from Metastatic Colorectal Carcinoma Patients Treated with Polychemotherapy and Anti-EGFR Monoclonal Antibodies 151
Let‐7a‐5p, mir‐100‐5p, mir‐101‐3p, and mir‐199a‐3p hyperexpression as potential predictive biomarkers in early breast cancer patients 150
ERCC1 Induction after Oxaliplatin Exposure May Depend on KRAS Mutational Status in Colorectal Cancer Cell Line: In Vitro Veritas 149
An Innovative Scoring System to Select the Optimal Surgery in Breast Cancer after Neoadjuvant Chemotherapy 145
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation 143
Class 1, 2, and 3 BRAF-mutated metastatic colorectal cancer: A detailed clinical, pathologic, and molecular characterization 143
Radiotherapy benefit in oligoprogressive breast cancer: A retrospective analysis 141
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 139
Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy 137
Conservative Surgery in cT4 Breast Cancer: Single-Center Experience in the Neoadjuvant Setting 133
Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial 131
Case report: Vitiligo-like toxicity due to ribociclib during first-line treatment of metastatic breast cancer: two cases of premature interruption of therapy and exceptional response 129
Multigenic panels in breast cancer: Clinical utility and management of patients with pathogenic variants other than BRCA1/2 127
Impact on survival of primary tumor resection in patients with metastatic breast cancer: preliminary results of a retrospective analisys 127
Characteristics and risk factors for SARS-CoV-2 in children tested in the early phase of the pandemic: a cross-sectional study, Italy, 23 February to 24 May 2020 126
Role of radiomics in predicting early disease recurrence in locally advanced breast cancer patients: integration of radiomic features and RECIST criteria 125
Paradox CA 15-3 increase in metastatic breast cancer patients treated with everolimus: A change of paradigm in a case series 124
OlympiAD trial: moving to a next level of treatment for patients with BRCA mutation and her2-negative metastatic breast cancer 123
Usefulness of automated breast volume scanner (ABVS) for monitoring tumor response to neoadjuvant treatment in breast cancer patients: preliminary results 123
Cdk4/6 inhibitor treatments in patients with hormone receptor positive, her2 negative advanced breast cancer: Potential molecular mechanisms, clinical implications and future perspectives 123
A 10-miRNA risk score-based prediction model for pathological complete response to neoadjuvant chemotherapy in hormone receptor-positive breast cancer 122
Long-Term Safety of Level II Oncoplastic Surgery after Neoadjuvant Treatment for Locally Advanced Breast Cancer: A 20-Year Experience 121
Baseline 18F-FDG PET/CT for predicting pathological response to neoadjuvant chemotherapy and prognosis in locally advanced breast cancer patients: analysis of tumor and lymphoid organs metabolic parameters 121
Malignant Mesenchymal Tumors of the Breast: Current Challenges and New Perspectives on Primary Sarcomas and Malignant Phyllodes Tumors 121
Targeted Therapy in Advanced Gastric Carcinoma:the Future is Beginning 119
PI3K Inhibitors in Advanced Breast Cancer: The Past, The Present, New Challenges and Future Perspectives 118
Adjuvant denosumab in early breast cancer: a systematic review and meta-analysis of randomized controlled clinical trials 118
Prognostic Factors in Patients with Breast Cancer Liver Metastases Undergoing Liver Resection: Systematic Review and Meta-Analysis 118
Menopausal hormone therapy: What should be kept in mind for a personalized choice in a shared decision-making 118
Diffuse liver infiltration by lobular breast carcinoma: Shear wave elastography as gold standard imaging study. 117
Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force “Dermatology for Cancer Patients” International Study 115
Maintenance strategies after anti-EGFR-based induction in metastatic colorectal cancer: A systematic review and bayesian network meta-analysis 112
A 10-miRNA risk score-based prediction model for pathological complete response to neoadjuvant chemotherapy in hormone receptor-positive breast cancer 111
Neoadjuvant Chemotherapy in Breast Cancer: An Advanced Personalized Multidisciplinary Prehabilitation Model (APMP-M) to Optimize Outcomes 107
Lung adenocarcinoma presenting as a solitary gingival metastasis: a case report 105
Poor efficacy of palbociclib in second-line treatment of metastatic lobular breast cancer in a case series: Use before or never more? 105
Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Versus Cetuximab as Maintenance Therapy in First-Line Therapy for RAS and BRAF Wild-Type Metastatic Colorectal Cancer: Phase III ERMES Study 103
Level II Oncoplastic Surgery as an Alternative Option to Mastectomy with Immediate Breast Reconstruction in the Neoadjuvant Setting: A Multidisciplinary Single Center Experience 103
LUX-Lung 7: is there enough data for a final conclusion? 102
Association between background parenchymal enhancement and tumor response in patients with breast cancer receiving neoadjuvant chemotherapy 101
Impact on survival of primary tumor resection in patients with metastatic breast cancer: preliminary results of a retrospective analysis 99
Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope 98
Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors 97
From controversy to clarity: reimagining the role of CDK4/6 inhibitors in the adjuvant setting– a number needed to treat perspective 96
Phase II study of apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative metastatic breast cancer and clinical implications of monitoring ctDNA 96
Hepatectomy versus systemic therapy for liver-limited BRAF V600E-mutated colorectal liver metastases: multicentre retrospective study 94
Poor efficacy of palbociclib in second-line treatment of metastatic lobular breast cancer in a case series: Use before or never more? 94
How will artificial intelligence impact breast cancer research efficiency? 93
Treatment of locally advanced gastric cancer (LAGC): Back to lauren’s classification in pan– cancer analysis era? 92
Demystifying BRAF Mutation Status in Colorectal Liver Metastases: A Multi-institutional, Collaborative Approach to 6 Open Clinical Questions 91
Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse 88
Bevacizumab-based neoadjuvant chemotherapy for colorectal cancer liver metastases: Pitfalls and helpful tricks in a review for clinicians 87
The interference between oxaliplatin & anti-EGFR therapies: A different hypothesis to explain the 'unexplainable' 87
The Therapeutic Challenge of Disseminated Bone Marrow Metastasis From HR-Positive HER2-Negative Breast Cancer: Case Report and Review of the Literature 85
Definition of a tool to assess shared decision-making (SDM) on women with breast cancer: A value-based approach 80
Phase III study with FOLFIRI + cetuximab versus FOLFIRI + cetuximab followed by cetuximab alone in RAS and BRAF WT mCRC 79
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth 78
Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study 77
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting 77
Targeted therapy in advanced gastric carcinoma: The future is beginning 76
The combined effect and mechanism of antiangiogenic drugs and PD-L1 inhibitor on cell apoptosis in triple negative breast cancer 75
Automated breast volume scanner (ABVS) compared to handheld ultrasound (HHUS) and contrast-enhanced magnetic resonance imaging (CE-MRI) in the early assessment of breast cancer during neoadjuvant chemotherapy: an emerging role to monitoring tumor response? 71
Anthracycline-free or short-term regimen as adjuvant chemotherapy for operable breast cancer: A phase III randomized non-inferiority trial 70
New life for retrospective study in the precision oncology era 68
New challenges in multimodal workout of locally advanced breast cancer 67
Smoking habit and hospitalization for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related pneumonia: The unsolved paradox behind the evidence 65
Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors 65
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study 57
Long term outcomes of breast primary sarcomas and malignant phyllodes tumors: 20 years observational analysis of the BEAM∗ study group. (∗the breast European association for mesenchymal tumors) 53
To treat or no to treat: HER2 equivocal is the matter! 53
Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative study 53
Anti-tumour and anti-angiogenetic effects of zoledronic acid on human non-small-cell lung cancer cell line 52
Racial and ethnic disparities in breast cancer survival: critical appraisal of the data emerging from the randomized TAILORx 45
Totale 12.805
Salva come PNG Salva come JPEG
Categoria #
all - tutte 52.358
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 52.358
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022587 0 0 10 67 18 50 18 83 34 41 131 135
2022/20231.395 188 194 99 197 79 142 90 135 145 40 52 34
2023/2024748 40 164 30 34 38 151 53 43 16 19 75 85
2024/20252.005 37 28 135 59 134 51 69 57 203 312 540 380
2025/20266.044 738 265 428 901 867 255 1.027 273 375 409 272 234
2026/2027692 198 366 128 0 0 0 0 0 0 0 0 0
Totale 12.866